340 related articles for article (PubMed ID: 34077955)
21. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
22. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
[TBL] [Abstract][Full Text] [Related]
23. Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.
Wong KY; Yao Q; Yuan LQ; Li Z; Ma ESK; Chim CS
Sci Rep; 2018 Sep; 8(1):13522. PubMed ID: 30201956
[TBL] [Abstract][Full Text] [Related]
24. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
25. Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Ono Y; Sato K; Mizukami Y; Okumura T
Clin Chim Acta; 2023 Nov; 551():117590. PubMed ID: 37837907
[TBL] [Abstract][Full Text] [Related]
26. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
27. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
28. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
29. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
30. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Kobayashi Y; Chhoeu C; Li J; Price KS; Kiedrowski LA; Hutchins JL; Hardin AI; Wei Z; Hong F; Bahcall M; Gokhale PC; Jänne PA
Nature; 2022 Mar; 603(7900):335-342. PubMed ID: 35236983
[TBL] [Abstract][Full Text] [Related]
31. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
32. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
[TBL] [Abstract][Full Text] [Related]
33. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
34. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
35. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
36. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
37. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
38. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
39. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract][Full Text] [Related]
40. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
